http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-119322-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate | 2020-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcdd1f1b419b833bf05999d8f6dc08a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_596fc873764ba3bf30ac1174d2d5d008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd592f2c660f93028c949ceddba067d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9cae043b81bb7fa59a3088366ae1b25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e683dc0f6e8eb81653e79bb2c09d605b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08aa9a0ba83c3b64e64d5fb66a7eaaad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff1862b3e4d14d5df2937cd435b8c727 |
| publicationDate | 2021-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-119322-A1 |
| titleOfInvention | COMPOUNDS DERIVED FROM 1H-PYRIDO[1,2-A]PYRAZINE AS MAGL INHIBITORS |
| abstract | Pyrido-pyrazine derivatives such as monoacylglycerol lipase (MAGL) inhibitors, pharmaceutical compositions comprising them and their use for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and mental disorders. Claim 1: Compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein: R¹ is selected from the group consisting of: (i) C₆₋₁₄ aryl optionally substituted with 1 to 2 substituents independently selected from the group consisting of at C₁₋₆ alkoxy, halogen and a group of formula (2), (ii) 5 to 6 membered heteroaryl optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₆ alkoxy, -B (OH)₂, 5-6 membered heteroaryl, C₁₋₆ alkyl, and amino, and (iii) 5-14 membered heterocyclyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl and oxo, R² is selected from the group consisting of: (i) C₁₋₆ alkyl optionally substituted with 1 to 3 substituents independently selected from halogen, (ii) C₃₋₁₄ cycloalkyl, (iii) C₆₋₁₄ aryl optionally substituted with 1 to 2 substituents selected s independently of halogen, (iv) 5 to 14 membered heteroaryl optionally substituted with 1 to 3 substituents independently selected from halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and oxo, and (v) optionally substituted 5 to 14 membered heteroaryloxy with 1 to 3 substituents independently selected from halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and oxo, and (vi) 5 to 14 membered heterocyclyl optionally substituted with 1 to 3 substituents independently selected from halogen, C₁₋₆ alkyl, haloalkyl C₁₋₆ and oxo, R³ is selected from the group consisting of hydrogen, halogen, C₁₋₆ alkoxy, C₃₋₁₄ cycloalkyloxy, and hydroxy, R⁴ is selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, hydroxy-alkyl C₁₋₆, C₁₋₆-alkoxy-carbonyl, C₁₋₆-alkoxy-carbonyl-NH-, hydroxy, amino, carboxy, C₁₋₆-alkyl-C(O)-NH-, C₂₋₆-alkenyl-C(O)-NH -, carboxy-NH-, oxo, C₃₋₁₄-cycloalkyl, and hydroxy-C₃₋₁₄-cycloalkyl, L is selected from the group consisting of a co bond valent and -CH=CH-, A is selected from the group consisting of C₆₋₁₄ aryl, 5 to 14 membered heteroaryl, and 5 to 14 membered heterocyclyl, and n is 1, 2, 3, or 4. |
| priorityDate | 2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.